SRP6458
TFPI human
recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)
Synonym(s):
EPI, LACI, TFI, TFPI1
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.32
UNSPSC Code:
12352202
Biological source:
human
Recombinant:
expressed in HEK 293 cells
Assay:
≥95% (SDS-PAGE)
Form:
lyophilized
Mol wt:
calculated mol wt 30 kDa, observed mol wt 41-45 kDa (DTT-reduced. Protein migrates due to glycosylation. Asp 29 is the predicted N-terminal.)
Impurities:
<1 EU/μg endotoxin (LAL test)
biological source
human
recombinant
expressed in HEK 293 cells
tag
6-His tagged (C-terminus)
assay
≥95% (SDS-PAGE)
form
lyophilized
potency
<0.35 nM IC50
mol wt
calculated mol wt 30 kDa, observed mol wt 41-45 kDa (DTT-reduced. Protein migrates due to glycosylation. Asp 29 is the predicted N-terminal.)
packaging
pkg of 10 μg
impurities
<1 EU/μg endotoxin (LAL test)
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... TFPI(7035)
General description
The TFPI (tissue factor pathway inhibitor) gene is mapped to human chromosome 2q32.1. This protein exists in two isoforms TFPIα and TFPIβ.
Tissue factor pathway inhibitor (TFPI) also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a Nterminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a Cterminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The Cterminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.
Biochem/physiol Actions
Inhibition of tissue factor function and thrombus formation by TFPI (tissue factor pathway inhibitor) is a major reason for ischemic stroke in carotid artery disease. The main function of TFPI is to regulate blood coagulation system. It possess both anticoagulant and antimetastatic action. This protein is prominently localized to medial and neointimal smooth muscle cells, macrophages and T-cells of atherosclerotic plaques. Upregulation of the TFPI gene is observed in atherosclerosis. Mutation in the TFPI gene leads to the risk of coronary artery disease.
Physical form
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.
Preparation Note
Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 μg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Increased expression of TFPI in human carotid stenosis
Stavik B, et al.
Thrombosis Research, 155(5), 31-37 (2017)
Significant genetic association of a functional TFPI variant with circulating fibrinogen levels and coronary artery disease
Naji DH, et al.
Molecular Genetics and Genomics, 293(1), 119-128 (2018)
Teresa C Assumpção et al.
PLoS neglected tropical diseases, 10(1), e0004298-e0004298 (2016-01-09)
Hematophagous mosquitos and ticks avoid host hemostatic system through expression of enzyme inhibitors targeting proteolytic reactions of the coagulation and complement cascades. While most inhibitors characterized to date were found in the salivary glands, relatively few others have been identified
John W Avery et al.
PloS one, 7(2), e31090-e31090 (2012-02-22)
Low birth weight and fetal loss are commonly attributed to malaria in endemic areas, but the cellular and molecular mechanisms that underlie these poor birth outcomes are incompletely understood. Increasing evidence suggests that dysregulated hemostasis is important in malaria pathogenesis
Harald Haidl et al.
Scientific reports, 9(1), 8014-8014 (2019-05-31)
Healthy neonates exhibit a well-functioning haemostatic system despite peculiarities regarding composition of clotting factors and inhibitors as well as impaired platelet aggregation. Thrombocytopenia and severe bleeding events are feared in sick infants. Recombinant factor VIIa (rFVIIa) is a haemostatic agent
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service